Ron
Analyst
J.P. Morgan
Equibles does not estimate personal net worth.
About Ron
Ron is recorded as Analyst at J.P. Morgan. Ron has spoken on 1 earnings call and 1 other investor event across 2 companies, most recently for Kyverna Therapeutics, Inc. on April 22, 2026. Those appearances were for Kyverna Therapeutics, Inc. (KYTX) and Vir Biotechnology, Inc. (VIR). The companies whose calls Ron spoke on are classified in the Healthcare sector.
Ron on recent calls
“Looking ahead into the approval for MIVCELL and SPS, how should we think about the label language? Do you see potential for this therapy to be approved for the broad SPS population or do you anticipate approval will be dedicated only to GAD65 or VLAIR positive patients?”
“I wanted to ask, how does the recent Bolivaritide update and test your thinking around the potential finite versus long-term chronic treatment with a combination for HDV?”
Affiliation history
-
J.P. Morgan
Analyst
Transcript header (unverified)
Current